Toshinobu Hayashi

Associate Professor

Fukuoka University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

ORCID

Google Scholar

About

Dr. Toshinobu Hayashi is an Associate Professor at Fukuoka University, Japan. His research primarily focuses on chemotherapy-related side effects, including nausea, vomiting, and nephrotoxicity, as well as the effectiveness of various antiemetic therapies. Dr. Hayashi's recent work includes multicenter trials and observational studies assessing treatment outcomes in older cancer patients and exploring the clinical benefits of novel therapeutic strategies.

Toshinobu Hayashi

Research Interests

Explore related searches

Contact this professor

About

Articles (21)

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity

Assessing the ability of the Cancer and Aging Research Group tool to predict chemotherapy toxicity in older Japanese patients: A prospective observational study

Effects of renin-angiotensin system inhibitor and beta-blocker use on mortality in older patients with heart failure with reduced ejection fraction in Japan

Impact of the First Twenty-Four-Hour Area Under the Concentration-Time Curve/Minimum Inhibitory Concentration of Vancomycin on Treatment Outcomes in Patients With Methicillin-Resistant <i>Staphylococcus </i>aureus Bacteremia

Adrenaline-resistant anaphylactic shock caused by contrast medium in a patient after risperidone overdose: a case report

Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer

Effectiveness of palonosetron, 1-day dexamethasone, and aprepitant in patients undergoing carboplatin-based chemotherapy

Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy

Assisted Living and Medication Adherence in Super-aged Patients With Heart Failure in the Japanese Population

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy

Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score–matched analysis

Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B)

Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: Comparison with tissue plasminogen activator

Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis

5HT<sub>3</sub>RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis

Effects of recommended consultation practice using fracture risk assessment tool and fracture evaluation questionnaire for early detection of osteoporosis at community pharmacies

Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score–matched analysis

Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk

Collaborators (1)

Fumitaka Mizuki

How do I reach out?

Meet Kite AI